Michael Egholm - Jan 5, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
President & CEO, Director
Signature
/s/ Michael Egholm by Agnieszka Gallagher, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
Jan 5, 2024
Transactions value $
$0
Form type
4
Date filed
4/5/2024, 06:59 PM
Previous filing
Apr 6, 2023
Next filing
Apr 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +9.01K +4.16% $0.00 226K Jan 5, 2024 Direct F1
transaction LAB Common Stock Options Exercise $0 +197K +87.14% $0.00 422K Apr 4, 2024 Direct
transaction LAB Common Stock Award $0 +212K +50.26% $0.00 634K Apr 5, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Restricted Stock Units Options Exercise $0 -197K -33.33% $0.00 393K Apr 4, 2024 Common Stock 197K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger.
F2 On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024.
F3 Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F4 On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.